Colistimethate
- Generic Name
- Colistimethate
- Brand Names
- Colobreathe, Coly Mycin M, Xylistin
- Drug Type
- Small Molecule
- Chemical Formula
- C58H105N16O28S5
- CAS Number
- 12705-41-8
- Unique Ingredient Identifier
- DL2R53P963
- Background
Colistimethate is an antibiotic that has been shown to have bactericidal activity against aerobic gram-negative microorganisms. Colistimethate is particularly indicated when the infection is caused by sensitive strains of Pseudomonas aeruginosa.
- Indication
For the treatment of acute or chronic infections due to sensitive strains of certain gram-negative bacilli, particularly Pseudomonas aeruginosa.
- Associated Conditions
- Bacterial Infections
Evaluation of Pharmacokinetic and Pharmacodynamic Properties of Intravenous Colistimethate Sodium
- First Posted Date
- 2014-11-11
- Last Posted Date
- 2019-06-24
- Lead Sponsor
- University of Colorado, Denver
- Target Recruit Count
- 16
- Registration Number
- NCT02288429
- Locations
- šŗšø
University of Colorado Hospital, Aurora, California, United States
Evaluation of Inhaled Antibiotics on Bacterial Diversity and Richness in the Cystic Fibrosis Lung
- Conditions
- Cystic Fibrosis
- Interventions
- Drug: TOBIā¢ Podhalerā¢ 112 mg inhaled twice daily
- First Posted Date
- 2014-04-14
- Last Posted Date
- 2018-03-12
- Lead Sponsor
- Dartmouth-Hitchcock Medical Center
- Target Recruit Count
- 1
- Registration Number
- NCT02113397
- Locations
- šŗšø
Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States
Efficacy and Safety of Colistimethate Sodium Injection Vial to Treat Hospital-acquired Pneumonia in Adults
- First Posted Date
- 2013-09-12
- Last Posted Date
- 2013-09-12
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 60
- Registration Number
- NCT01940731
- Locations
- šØš³
The Seond Hospital of Jilin University, Jilin, China
šØš³Huashan Hospital ,Fudan University, Shanghai, China
šØš³Shanghai Pulmonary Hospital, Shanghai, China
Aerosolized and Intravenous Colistin in Healthy Adults
- Conditions
- Pneumococcal InfectionPneumoniaPathogen Resistance
- Interventions
- First Posted Date
- 2013-05-29
- Last Posted Date
- 2020-03-02
- Target Recruit Count
- 27
- Registration Number
- NCT01863719
- Locations
- šŗšø
Johns Hopkins Bayview Medical Center - Infectious Diseases, Baltimore, Maryland, United States
šŗšøCase Western Reserve University - Case Medical Center - Infectious Disease & HIV Medicine, Cleveland, Ohio, United States
Ease of Use and Microbial Contamination of Tobramycin Inhalation Powder (TIP) Versus Nebulised Tobramycin Inhalation Solution (TIS) and Nebulised Colistimethate (COLI)
- Conditions
- Cystic Fibrosis
- Interventions
- First Posted Date
- 2013-05-01
- Last Posted Date
- 2016-07-27
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 60
- Registration Number
- NCT01844778
- Locations
- š¬š§
Novartis Investigative Site, Newcastle upon Tyne, United Kingdom
Phase I Study of Colistin Methanesulfonate Sodium
- Conditions
- Infections, Pseudomonas
- Interventions
- Drug: Saline
- First Posted Date
- 2011-10-10
- Last Posted Date
- 2017-07-21
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 22
- Registration Number
- NCT01449838
- Locations
- š¦šŗ
GSK Investigational Site, Randwick, New South Wales, Australia
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.